ClinicalTrials.gg
RecruitingNCT05837598Updated Aug 3, 2023

Adapting the Tumor Board Model for Mental Illness and Cancer

An interventional study of Virtual Cancer and Mental Health Tumor Board in Cancer, Severe Major Depression and Schizophrenia, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-03.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study examines the feasibility and acceptability of a virtual tumor board for cancer and mental illness for patients with serious mental illness and a new cancer diagnosis. The study also examines the impact on patient care, psychiatric symptoms, and clinician self-efficacy in managing this population.

Read the detailed description

Individuals with serious mental illness (SMI) experience increased cancer mortality because of inequities in cancer care. Access to mental health and cancer care remains inadequate. Virtual tumor boards have been associated with higher rates of patients receiving guideline-concordant cancer care, but these tumor boards have not been adapted for cancer and mental illness. A virtual cancer and mental health tumor board intervention has potential to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, and may address barriers to cancer and mental health care. The purpose of this study is to examine the feasibility and acceptability of a virtual tumor board for cancer and mental illness for our target population for patients and clinicians. We will also explore changes in cancer care, psychiatric symptoms, and clinician self-efficacy in managing this population. This study is a single-arm pilot (n = 30) based at a cancer center affiliate and the surrounding community. The intervention includes proactive identification using a registry, bi-monthly virtual equity tumor board focused on cancer and mental health using HIPAA-compliant videoconference that uses co-learning, assessment of barriers to cancer care, strengths, and goals of care, creating plans that identify who is responsible for next steps and patient communication, and relaying recommendations to patients and the treating oncology team.

02

Conditions studied

  • Cancer
  • Severe Major Depression
  • Schizophrenia
  • Bipolar Disorder
  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer

Keywords

  • Cancer Care
  • Major Depression and Cancer
  • Schizophrenia and Cancer
  • Bipolar disorder and Cancer
  • Lung Cancer
  • Breast Cancer
  • Head and Neck Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancer
  • Schizophrenia
  • Bipolar Disorder
  • Major Depression
  • Health equity
  • Mental disorders
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old
  2. Verbal fluency in English
  3. SMI (schizophrenia spectrum disorder, bipolar disorder, or major depressive disorder with either prior psychiatric hospitalization, history of suicide attempt/suicidal ideation, Medicaid insurance, and/or comorbid alcohol or opioid use disorder) confirmed by diagnostic evaluation of study psychiatrist
  4. New invasive stage I-IV breast, lung, gastrointestinal, genitourinary, or head and neck cancer (highly suspected or confirmed according to documentation by the oncologist or pathology)
  5. Oncology consultation at or referral to a MGH Danvers within the past 8 weeks

Exclusion criteria

Exclusion Criteria:

  1. Have cognitive impairment severe enough to interfere with completing brief study assessments or providing and does not have a guardian who can provide consent
  2. Recurrence of same cancer type
  3. Do not have verbal fluency in English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Tumor Board Arm

    This intervention has three parts: Part 1: Proactive identification and assessment of patient needs, values, psychiatric symptoms, and illness understanding Part 2: Virtual tumor board discussion o Bring together expertise in mental illness and cancer, the interdisciplinary team will co-design an integrated cancer and mental health treatment plan. Key strategies include: addressing resource-related barriers to care, framing next steps in terms of patient values, and identifying action steps to address barriers to psycho-oncology/specialty oncology expertise Part 3: Closed Loop Communication o Tumor board recommendations shared with treating oncologist, documented in medical record, and shared with patient. Team tracks steps taken to address barriers to care and follows up with patient at 12 weeks.

    Behavioral: Virtual Cancer and Mental Health Tumor Board

Interventions

  • BehavioralVirtual Cancer and Mental Health Tumor Board

    The Virtual Cancer and Mental Health Tumor Board intervention aims to increase access to psycho-oncology and oncology expertise, facilitate clinician communication, build understanding of the person's needs and strengths, and address barriers to care. Strategies include a proactive assessment of illness understanding, psychiatric history, and barriers to care followed by development of an integrated cancer and mental health treatment plan during the tumor board session that is framed in terms of patient values and addresses barriers to accessing psycho-oncology and specialty oncology expertise. These recommendations will be shared with treating oncologists, documented in the medical record, and shared with the patient. Patients will receive a transition phone call at 12 weeks.

06

What researchers measure

Primary outcomes

  1. Patient enrollment assessed by consent rate.

    The investigators will evaluate program feasibility through patient enrollment by examining consent rates (60% of eligible patients consent).

    Time frame: At baseline

  2. Patient trial completion assessed by number of patients who complete study assessments and trial procedures.

    The investigators will evaluate trial completion assessed by number of patients who complete study assessments and trial procedures (75% of patient participants have baseline targeted assessment, have tumor board recommendations communicated with them, and complete 12-week assessment of psychiatric symptoms and barriers to cancer care).

    Time frame: 12 weeks from study enrollment

  3. Patient satisfaction assessed by patient feedback questionnaire.

    The investigators will evaluate program acceptability through patient intervention satisfaction by a patient feedback questionnaire (exit interview surveys with participating patients regarding the usefulness of the intervention) at 12 weeks.

    Time frame: 12 weeks from study enrollment

Secondary outcomes

  1. Volume of tumor board session attendance by tumor board participants.

    The investigators will evaluate program feasibility by tracking volume of tumor board session attendance (feasibility defined as participants attending 80% of sessions when patients/clients discussed).

    Time frame: 24 weeks from study enrollment

  2. Tumor board participant satisfaction assessed by tumor board participant feedback questionnaire.

    The investigators will evaluate program acceptability by examining participant intervention satisfaction (feedback questionnaire at end of study period regarding the acceptability and helpfulness of the virtual tumor board model).

    Time frame: 24 weeks from study enrollment

  3. Number of participants contributing to multi-disciplinary representation at tumor board sessions.

    The investigators will evaluate program feasibility by examining the amount of multi-disciplinary representation at tumor board sessions (\>70% of sessions include representation from oncology/cancer center affiliate, community mental health, and psycho-oncology).

    Time frame: 24 weeks from study enrollment

  4. Percentage of tumor board participants participating in tumor board session.

    The investigators will evaluate program feasibility by tracking percentage of tumor board participants participating in tumor board sessions (80% of participants complete intra-session feedback questionnaire).

    Time frame: 24 weeks from study enrollment

  5. Percentage of tumor board participants completing study questionnaires.

    The investigators will evaluate program feasibility by examining completion of study measures (70% of participants complete 12-week- and 24-week measures).

    Time frame: 24 weeks from study enrollment

  6. Tumor board participant satisfaction assessed by in-session feedback questionnaire.

    The investigators will evaluate program acceptability by examining participant intervention satisfaction (in-session feedback questionnaire regarding the acceptability and helpfulness of the virtual tumor board model).

    Time frame: 24 weeks from study enrollment

Other outcomes

  1. Change in patient psychiatric illness severity assessed by Brief Psychiatric Rating Scale (BPRS).

    Investigators will assess change in patient psychiatric illness severity using the Brief Psychiatric Rating Scale (BPRS). This questionnaire is 24 items, each question rated on a 7-point scale of severity ranging from "not present" to "extremely severe." Scores vary from 24 to 168 with higher scores indicating more severe psychiatric illness.

    Time frame: 12 weeks from study enrollment

  2. Change in patient anxiety symptoms assessed by the Generalized Anxiety Disorder-7 (GAD-7).

    Investigators will assess change in patient anxiety symptoms using the Generalized Anxiety Disorder-7 (GAD-7). This questionnaire is 7 items, and responses range from "0" (not at all) to "3" (nearly every day), and scores range from 0 to 21, with higher scores indicating greater anxiety.

    Time frame: 12 weeks from study enrollment

  3. Change in patient depression symptoms assessed by Patient Health Questionnaire-9 (PHQ-9).

    Investigators will assess change in patient depression symptoms using the Patient Health Questionnaire-9 (PHQ-9). This questionnaire is 9 items, and responses range from "0" (not at all) to "3" (nearly every day), and scores range from 0 to 27, with higher scores indicating greater depression.

    Time frame: 12 weeks from study enrollment

  4. Change in patient quality of life assessed by Functional Assessment of Cancer Therapy - General (FACT-G).

    Investigators will assess change in patient quality of life using the Functional Assessment of Cancer Therapy - General (FACT-G). This questionnaire is 27 items, and response are on a 5-point rating scale from "0" (not at all) to "4" (very much). Scores range from 0 - 108, and higher scores indicate better quality of life.

    Time frame: 12 weeks from study enrollment

  5. Change in tumor board participant self-efficacy assessed by Tumor Board Participant Self-Efficacy Assessment.

    Investigators will assess change in tumor board participant self-efficacy using the Tumor Board Participant Self-Efficacy Assessment. This questionnaire is 22 items, with scores ranging from 0 - 44, and higher scores indicating more self-efficacy.

    Time frame: 24 weeks from study enrollment

  6. Change in tumor board participant burnout assessed by modified Maslach Burnout Inventory survey.

    Investigators will assess change in tumor board participant burnout using a modified Maslach Burnout Inventory survey. This questionnaire is 22 items, and responses range from "0" (never) to "6" (every day). Section A scores range from 0 - 42, with a higher score indicating more burnout. Section B scores range from 0 - 42, with a higher score indicating more burnout. Section C scores range from 0 - 48, with a higher score indicating less burnout.

    Time frame: 24 weeks from study enrollment

  7. Disruptions in patient cancer care assessed by electronic medical record review.

    Number of participants with Disruptions in patient cancer care assessed by electronic medical record review. Disruptions are defined as delays, deviations in cancer care recommended, and interruptions in planned cancer treatment.

    Time frame: 24 weeks from study enrollment

  8. Patient receipt of mental health care assess by electronic medical record review.

    Number of participants with documented receipt of mental health care for patients assessed by electronic medical record review.

    Time frame: 24 weeks from study enrollment

07

Study locations

1 of 1 sites recruiting
  • Mass General/North Shore Center for Outpatient Care
    Danvers, Massachusetts 01923, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2024, 12 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 12 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
May 1, 2023
StartActual
May 31, 2023
Primary completionEst.
May 31, 2024
CompletionEst.
May 31, 2024
Last update
Aug 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05837598
Collaborators
Trefler Foundation
Responsible party
Kelly Edwards Irwin (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
May 1, 2023
Start date
May 31, 2023
Primary completion
May 31, 2024 (estimated)
Completion
May 31, 2024 (estimated)
Last update
Aug 3, 2023

Study contacts

Kelly Irwin, MD, MPH
Contact
kirwin1@partners.org
617-643-4453

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion